Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)

NCT04870164 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
53
Enrollment
INDUSTRY
Sponsor class

Stopped Due to hypersensitivity observed in 3 subjects, although no stopping rules were met, the Sponsor decided to halt recruitment for further investigation. After analysis of PK, i.m. administration was not required, and recruitment stopped.

Conditions

Interventions

Sponsor

Molecular Partners AG